Dergiler / Turkish Journal of Urology / 2019 / Cilt: 45 - Sayı: 1

Paraneoplastic hyperbilirubinemia in metastatic prostate cancer and review of the current literature

Sayfa
70–72
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

We observed improvement of his cholestasis with hormonotherapyused for prostate cancer.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Paraneoplastic syndromes are functional clinical disorders caused by the direct effect of the primary tumoror metastasis.
📊
Temel Bulgular & Veri:The initial presenting symptom of the patients may be associated with paraneoplastic manifestations.
💡
Sonuç & Katkı:We observed improvement of his cholestasis with hormonotherapyused for prostate cancer.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Paraneoplastic syndromes are functional clinical disorders caused by the direct effect of the primary tumoror metastasis. The initial presenting symptom of the patients may be associated with paraneoplastic manifestations. Paraneoplastic cholestasis is most frequently defined in association with renal cell carcinoma(Stauffer's syndrome), but it is an extremely rare clinical entity seen in association with prostate cancer. Etiology of cholestasis was investigated in the case diagnosed as metastatic prostate cancer who applied to thegastroenterology outpatient clinic due to complaints of ascites and jaundice that established the diagnosisof paraneoplastic hyperbilirubinemia. We observed improvement of his cholestasis with hormonotherapyused for prostate cancer.

🔖

Bu Makaleye Atıf Yap

GÖKÇEN, P., GÖKÇEN, K., ÇAKMAK, E., GÖKÇE, G. (2019). Paraneoplastic hyperbilirubinemia in metastatic prostate cancer and review of the current literature. Turkish Journal of Urology, Cilt: 45 - Sayı: 1, 70–72. https://ajindex.com/articles/379790

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (2)

  1. Trauner M, Fickert P, Stauber RE. Inflammation-induced cholestasis. J Gastroenterol Hepatol 1999;14:946-59. [CrossRef] Gil H, de Wazieres B, Desmurs H, Fest T, Dupond JL. Stauffer’s syndrome disclosing kidney cancer: another cause of inflamatory syndrome with anicteric cholestasis. Rev Med Interne 1995;16:775-7. [CrossRef] Okano A, Ohana M, Kusumi F. Idiopathic cholestatic jaundice may be a paraneoplastic manifestation of underlying malignancy: a case of prostate cancer. Clin J Gastroenterol 2014;7:278-82. [CrossRef] Hong MK, Kong J, Namdarian B, Longano A, Grummer J, Hovens CM, et al. Paraneoplastic syndromes in prostate cancer. Nat Rev Urol 2010;7:681-92. [CrossRef] Dourakis SP, Sinani C, Deutsch M, Dimitriadou E, Hadziyanis SJ. Cholestatic jaundice as a paraneoplastic manifestation of renal cell carcinoma. Eur J Gastroenterol Hepatol 1997;9:311-4. [CrossRef] Nyugen V, Gurney H, van der Poorten D. Paraneoplastic hepatic dysfunction in metastatic prostate cancer: the role of cytokine dysregulation. J Clin Oncol 2011;29:e21-3. Chung TD, Yu JJ, Spiotto MT, Bartkowski M, Simons JW. Characterization of the role of IL-6 in the progression of prostate cancer. Prostate 1999;38:199-207. [CrossRef] Reddy AN, Grosberg SJ, Wapnick S. Intermittent cholestatic jaundice and nonmetastatic prostate cancer. Arch Intern Med 1977;137:1616-8. [CrossRef] Koruk M, Buyukberber M, Savas C, Kadayifci A. Paraneoplastic cholestasis associated with prostate carcinoma. Turk J Gastroenterol 2004;15:53-5.
  2. Moller S, Iverson P, Franzmann MB. Flutamide induced liver failure. J Hepatology 1990;10:342-9. [CrossRef]